GlassScriptPhysician profile
Lawrence S Mendelson
NPI 1851396600
$14,164.17
in general payments reported to CMS, 2019-2025
41 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,806 · 2020: $699 · 2021: $1,578 · 2022: $2,830 · 2023: $2,415 · 2024: $2,132 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,251.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,838.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,656.95 | 2019-2024 | Xarelto |
| Amgen INC. | $1,443.16 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,312.21 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,292.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $760.62 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $713.37 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Sanofi-Aventis U.S. LLC | $657.71 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $475.92 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $386.56 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $349.78 | 2019-2025 | Watchman Access System |
| Amarin Pharma, INC. | $326.83 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $278.39 | 2019-2025 | Onpattro, Amvuttra |
| Scpharmaceuticals INC. | $277.15 | 2024-2025 | |
| Heartflow, INC. | $256.78 | 2022-2023 | Ffrct |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $237.18 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $224.64 | 2019-2025 | Evkeeza |
| Daiichi Sankyo INC. | $191.18 | 2022-2025 | Injectafer |
| Kiniksa Pharmaceuticals, LTD. | $165.76 | 2022-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $152.18 | 2024 | Arcalyst |
| Abbott Laboratories | $135.34 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Esperion Therapeutics, INC. | $116.48 | 2022-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $112.89 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $107.14 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $84.28 | 2019 | |
| Lundbeck LLC | $66.12 | 2019 | |
| W. L. Gore & Associates, INC. | $61.28 | 2022 | |
| Veryan Medical Incorporated | $58.86 | 2021 | |
| Biotronik INC. | $55.82 | 2022-2023 | Biomonitor, Acticor 7 Vr-T Dx, Edora 8 Dr-T |
| Novo Nordisk INC | $45.38 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Abiomed | $44.72 | 2024 | Impella |
| Altathera Pharmaceuticals LLC | $43.98 | 2023-2024 | Sotalol Hydrochloride |
| Portola Pharmaceuticals, LLC | $37.57 | 2019 | |
| Edwards Lifesciences Corporation | $35.33 | 2019-2022 | |
| Philips North America LLC | $32.69 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.36 | 2025 | |
| Tactile Systems Technology INC | $26.80 | 2024 | Flexitouch Plus, Entre Plus |
| Akcea Therapeutics, INC. | $23.22 | 2020 | |
| Resmed Corp | $19.61 | 2023 | |
| Arbor Pharmaceuticals, INC. | $14.68 | 2019 | |
| Medtronic Vascular, INC. | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.